Back

Exploring the effects of SGLT2 inhibition in ongoing trials.

25 August 2018 (16:40 - 16:55)
Organised by:
Congress Presentation Part of: Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice Diabetes and the Heart ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Subodh Verma

St. Michael's Hospital, Toronto (Canada)

5 More presentations in this session

Presentation thumbnail
Welcome and introduction - Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice.
Professor N. Marx (Aachen, DE)
Presentation thumbnail
Evidence-based approaches to reducing premature cardiovascular mortality in patients with type 2 diabetes and established cardiovascular disease.
Professor D. McGuire (Dallas, US)
Presentation thumbnail
Applying evidence in practice: appropriate use of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in the cardiology clinic.
Doctor J. Udell (Toronto, CA) Professor N. Sattar (Glasgow, GB)
Presentation thumbnail
Advancing the standard of care in patients with type 2 diabetes and established cardiovascular disease: how can we improve patient outcomes? .
Professor N. Marx (Aachen, DE) Professor D. McGuire (Dallas, US) Doctor J. Udell (Toronto, CA) Professor S. Verma (Toronto, CA) Professor N. Sattar (Glasgow, GB)
Presentation thumbnail
Summary and close - Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice.
Professor N. Marx (Aachen, DE)

Access the full session

Session thumbnail
Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice

The Event

Event poster

ESC Congress 2018

25 August 2018 16:40 CET
You may be interested in
thumbnail
Congress Presentation
Cardiovascular benefits of SGLT2i in type 2 diabetes without heart failure: a subgroup analysis
30 August 2025
thumbnail
Congress Presentation
SOGALDI­PEF: SOdium-Glucose cotransporter 2 inhibitor with and without an ALDosterone AntagonIst for heart failure with preserved ejection fraction
17 May 2025
thumbnail
Congress Presentation
Patient vascular model reveals anti-inflammatory effects of SGLT2 inhibitor by modulating endothelial-T cell crosstalk
31 August 2025
thumbnail
Congress Presentation
Gliflozines in active cancer patients with heart failure: final results on safety and effectiveness in the observational TOSCA trial
20 June 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources